ArticleNutrition and metabolic insights2026
A Probiotic Nutritional Supplement Improves Glycemic Control and Biomarkers of Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus.
Article in Nutrition and metabolic insights, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: BeaT-2/Sugarburner is a nutritional supplement based on a co-existing microbial consortium of bacterial strains. The purpose of this study was to investigate potential beneficial effects of the supplement versus placebo on glycemic control and on biomarkers of inflammation, insulin resistance and ß-cell dysfunction. Methods: A total of 40 Patients with type 2 diabetes (31 male, 9 female, age:65.5 ± 8.0 years, BMI: 33.6 ± 5.5 kg/m Results: Time in range was stable with BeaT-2 between weeks 0 and 2 versus weeks 4 and 6, while it slightly impaired with placebo (-4%, n.s.). At endpoint, there were significant improvements versus baseline with BeaT-2, but not with placebo for biomarkers of glycemic control (BeaT-2 vs Placebo, HbA1c: -0.3% vs 0.1%, fasting glucose: -14% vs +8%, both Conclusion: The results observed with BeaT-2 were comprehensively indicative for improvements in the cardiometabolic situation. BeaT-2 may be a valuable supplement to any existing treatment combination in patients with type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.